CT
Viracta Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Nanatinostat + Valganciclovir (Nana-val) | Relapsed/Refractory EBV-positive Lymphomas (including PTCL, CTCL, DLBCL) | Phase 2 |
| Platform expansion | Other virus-associated cancers (KSHV, HPV, HBV) | Preclinical |
Leadership Team at Viracta Therapeutics
DS
Darren S. Cline
Chief Executive Officer and Director
DR
Daniel R. Chevallard
Chief Operating Officer and Chief Financial Officer
IR
Ivor Royston
Founder and Chairman of the Board
RD
Roger D. Dansey
President of Research and Development and Chief Medical Officer
TB
Teresa Bair
Senior Vice President, Clinical Development
SA
Sunil Agarwal
Senior Vice President, Early Development and Translational Medicine
BJ
Barry J. Simon
Board Member
JR
John R. Walker
Board Member
KE
Karin Eastham
Board Member
MR
Mark R. Lappe
Board Member